Association of interleukin-17 with peripheral spondyloarthropathic changes detected by musculoskeletal ultrasound in psoriatic patients

Elsayed, Ehsan K.; El‐Saadany, Hanan M.; Elfar, Nashwa N.; Elkhouly, Radwa M; Almaidany, Samah Hamdi; Gaber, Rasha A.

doi:10.1016/j.ejr.2019.04.011

Cited by 5 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings demonstrated a significant difference between PsA patients compared to patients with only psoriatic skin lesions regarding serum IL-17A levels. These results are consistent with the previous studies performed by Elsayed et al, 16 that revealed significant increases in the serum levels of IL-17A in psoriatic patients with rheumatic complaints when compared to those patients without rheumatic complaints.…”

Section: Discussionsupporting

confidence: 93%

“…Our study showed a significant positive correlation between IL‐17A and the PASI index of psoriatic skin lesion severity. In line with our results, Elsayed et al and Budamakuntla et al 16,17 reported a significant correlation between serum IL‐17A and psoriatic skin lesion severity regarding PASI score.…”

Section: Discussionsupporting

confidence: 93%

“…Despite this, the precise mechanism in considering high serum IL‐17A as a risk factor of developing early axSpA in asymptomatic patients and in nr‐axSpA patients is not clear. We could explain that according to our results and the results of others, regarding the significant deference of IL‐17A levels in PsA patients compared to patients with only psoriatic skin lesions, may be that when the level of IL‐17A increases, the susceptibility of articular affection increased 16 …”

Section: Discussionsupporting

confidence: 81%

“…We could explain that according to our results and the results of others, regarding the significant deference of IL-17A levels in PsA patients compared to patients with only psoriatic skin lesions, may be that when the level of IL-17A increases, the susceptibility of articular affection increased. 16 Therefore, regarding to our results in cases of high IL-17A (above 222.5 pg/ml) early sub-clinical axSpA changes should be suspected in asymptomatic psoriatic patients and in nr-axSpA patients.…”

Section: Discussionmentioning

confidence: 55%

See 3 more Smart Citations

Interleukin‐17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis

et al. 2020

View full text Add to dashboard Cite

Aim: Although the pathogenic mechanisms of psoriatic arthritis (PsA) are not completely clarified, evidence suggests that interleukin 17A (IL-17A)-mediated immune responses play a pivotal role in the disease. This is best underscored by the important clinical effectiveness of IL-17A inhibitors in psoriasis treatment. We aim to investigate the predictive value of IL-17A in detecting the early axial spondyloarthropic (SpA) changes in psoriatic patients. Methods: The study enrolled 100 patients with psoriasis, classified into group 1, included 62 patients with only psoriatic skin lesions (Ps), and group 2 included 38 patients with PsA, and 100 age and gender matched healthy volunteers. All participants were subjected to general and local clinical examination, laboratory assessment including IL-17A in the serum by means of enzyme-linked immunosorbent assay, and axial joint radiological assessment. Results: Our study included 60 males (60%) and 40 females (40%).The positive radiological findings of early axial SpA changes were found among 30.6% of the Ps group and among 84.2% of the PsA group. There were significant differences between patients with positive magnetic resonance imaging (MRI) findings of early axial SpA and patients with negative MRI findings in both groups regarding IL-17A levels. There was a significant association between IL-17A level and early axial SpA changes in psoriatic patients with a clear cutoff point (222.5). Conclusion: Our study can imply that IL-17A is a valuable, useful and low-cost biomarker in detecting early axial SpA changes in asymptomatic and nonradiographic axial SpA (nr-axial SpA) psoriatic patients that helps early management and prevent progressive axial involvement and disabilities.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 55%

See 2 more Smart Citations

Interleukin‐17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The significant role of IL-17 in SpA symptoms is in increasing the expression of genes associated with inflammation in target cells, including fibroblasts and keratinocytes, which causes an increase in the synthesis of cytokines, chemokines, and other mediators linked to the joints, skin, and entheses by enhancing TNF. There is evidence of decreased disease activity seen with IL-17 inhibitors in AS, psoriasis, and PsA [16].…”

Section: Introductionmentioning

confidence: 99%

Tenascin-C and Interleukin-17 Up-regulation in Axial Spondyloarthritis Patients

Al-Hindawi¹,

Al-Gebori²,

Alosami³

2023

RBJ

View full text Add to dashboard Cite

Background: Axial spondyloarthritis (axSpA) is an inflammatory, systemic rheumatic condition that mostly affects the axial skeleton. Tenascin-C (TN-C) is a hexameric glycoprotein of considerable size, upregulated in many inflammatory conditions, while Interleukin-17 (IL-17) a cytokine that plays an important role in SpA symptoms. Objective: to investigate the upregulation between the serum levels of TN-C and IL-17 in Iraqi axSpA patients and the disease characteristics. Patients and Methods: Seventy-four axSpA patients and 28 matched controls were studied. Fifty-four patients received a tumor necrosis factor inhibitor (TNFi) and 20 did not. Serum TN-C and IL-17 concentrations were determined using the ELISA technique. The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) was assessed. For statistical tests, Chi Square, Mann Whitney, Independent Samples T, and Pearson's correlation tests are used. Results: Patients mean age was 35.6±0.9 years, 65 males and 9 females, and disease duration was 5.18±0.6 years. 47.4% were smokers, 47% had inflammatory low back pain, and HLA-B27 was present in 91%. BASDAI mean was 6.1±0.4 in non-TNFi and 2.6±0.3 in those on TNFi. The serum TN-C concentration was significantly increased in patients, especially those on non-TNFi (79±9.6 pg/mL) compared to those on TNFi (69.1±3.2 pg/mL) and control (53±3.9 pg/mL) (p=0.003). Serum IL-17 was significantly elevated in those receiving TNFi (877.9±257 pg/mL) compared to non-TNFi (487.2±234 pg/mL) and control (182.4±36.6 pg/mL) (p=0.033). The TN-C significantly correlated with erythrocyte sedimentation rate (r=0.27, p=0.02) and with hemoglobin (Hb) concentration (r=0.26, p=0.02). TN-C and IL-17 were non-significantly related (r=0.14, p=0.2). Conclusions: axSpA Patients demonstrated high levels of serum TN-C, particularly in those not receiving TNFi, and high IL-17 levels in those receiving TNFi, suggesting that there is an association with tissue injury from the disease and stimulation of immunological and resident tissue cells. Patients who had not received TNFi showed significantly higher disease activity than others.

show abstract

Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients

Elwan

El‐Saadany

El-Banna

et al. 2021

The Egyptian Rheumatologist

View full text Add to dashboard Cite

Association of interleukin-17 with peripheral spondyloarthropathic changes detected by musculoskeletal ultrasound in psoriatic patients

Cited by 5 publications

References 30 publications

Interleukin‐17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis

Interleukin‐17A biomarker as a predictor for detection of early axial spondyloarthritis changes in patients with psoriasis

Tenascin-C and Interleukin-17 Up-regulation in Axial Spondyloarthritis Patients

Serum calprotectin as a potential biomarker for subclinical enthesitis in psoriatic patients

Contact Info

Product

Resources

About